Ryan

I, Ryan Hulse, nominated by USA, residing in USA, a member of the Medical and Chemicals Technical Options Committee declare as follows.

1. I have read the Conflict of Interest and Disclosure Guidelines for the Technology and Economic Assessment Panel, Its Technical Options Committees and Temporary Subsidiary Bodies (“the COI Guidelines”) as adopted by the Meeting of the Parties in Decision XXIV/8.
2. I am a Research and Development Director at Honeywell International. My responsibilities include leading the applications team in the development of new products in the areas Aerosol, Solvent, Refrigerants and Foam Blowing Agents.
3. This declaration constitutes my written agreement, pursuant to paragraph 8 of the COI Guidelines, to comply with the Guidelines.  I understand that this written agreement is a condition of my service.
4. My interests , and those of my personal partner and dependents, include the following
   • Proprietary interests: I have proprietary interest in a substance, technology or process to be considered by TEAP or any of its TOCs or temporary subsidiary bodies (e.g. task forces). As part of my work at Honeywell I have developed aerosol and solvent alternatives to CFC and HCFCs.  These rights for the patents are wholly owned by Honeywell.
   • Financial interests: I do not have ownership, shares or bonds in an entity with an interest in the subject matter of the meeting or work. 
   • Employment, consultancy, directorship or other positions: Honeywell has interest in the topics of the Montreal Protocol in that they are developing low global warming potential and non-ozone depletion potential alternatives to current CFC and HCFCs.
   • Government advice and other policy development: none
   • Paid research activities, fellowships or grants: none
   • Other interests:
5. The source of funding for my participation in the work of the Medical and Chemicals Technical Options Committee is from Honeywell Int.
6. Pursuant to paragraph 11 of the COI Guidelines, I declare that I not declined to disclose information falling within paragraph 10 of those Guidelines
7. I undertake to disclose any material change to any of the above information, pursuant to paragraph 9 of the COI Guidelines, within 30 days of any such change.
8. I undertake to make further declarations of interest annually for so long as I remain a member of the Medical and Chemicals Technical Options Committee.
9. I understand that this DOI will expire no later than one year after I have signed it.

Name: Ryan Hulse
Date: April 19, 2021